Alzheimer's Disease and the Amyloid-beta Peptide

Overview

Journal J Alzheimers Dis

Publisher Sage Publications

Specialties Geriatrics
Neurology

Date 2010 Jan 12

PMID 20061647

Citations 682

Authors

M Paul Murphy

Harry LeVine 3rd

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) pathogenesis is widely believed to be driven by the production and deposition of the amyloid-beta peptide (Abeta). For many years, investigators have been puzzled by the weak to nonexistent correlation between the amount of neuritic plaque pathology in the human brain and the degree of clinical dementia. Recent advances in our understanding of the development of amyloid pathology have helped solve this mystery. Substantial evidence now indicates that the solubility of Abeta, and the quantity of Abeta in different pools, may be more closely related to disease state. The composition of these pools of Abeta reflects different populations of amyloid deposits and has definite correlates with the clinical status of the patient. Imaging technologies, including new amyloid imaging agents based on the chemical structure of histologic dyes, are now making it possible to track amyloid pathology along with disease progression in the living patient. Interestingly, these approaches indicate that the Abeta deposited in AD is different from that found in animal models. In general, deposited Abeta is more easily cleared from the brain in animal models and does not show the same physical and biochemical characteristics as the amyloid found in AD. This raises important issues regarding the development and testing of future therapeutic agents.

Citing Articles

Decoding the Role of Neurotrophins in Glycogen Synthase Kinase 3-Beta Regulation in Alzheimer's Disease.

Rahmatkar S, Singh D Mol Neurobiol. 2025; .

PMID: 40014269 DOI: 10.1007/s12035-025-04776-x.

Metabolic Profiling of Brain Tissue and Brain-Derived Extracellular Vesicles in Alzheimer's Disease.

Hernandez P, Rackles E, Alboniga O, Martinez-Lage P, Camacho E, Onaindia A J Extracell Vesicles. 2025; 14(2):e70043.

PMID: 39901643 PMC: 11791017. DOI: 10.1002/jev2.70043.

Phytomedicine Potential of Root and Its Constituents: Targeting Alzheimer's Disease.

Summat R, Waiwut P, Daodee S, Nualkaew N, Phemphunananchai K, Arsito P Plants (Basel). 2025; 14(2).

PMID: 39861577 PMC: 11769049. DOI: 10.3390/plants14020223.

Associations Between Diabetes Mellitus and Neurodegenerative Diseases.

Szablewski L Int J Mol Sci. 2025; 26(2).

PMID: 39859258 PMC: 11765393. DOI: 10.3390/ijms26020542.

VDAC1: A Key Player in the Mitochondrial Landscape of Neurodegeneration.

Argueti-Ostrovsky S, Barel S, Kahn J, Israelson A Biomolecules. 2025; 15(1).

PMID: 39858428 PMC: 11762377. DOI: 10.3390/biom15010033.

References

Kimberly W, LaVoie M, Ostaszewski B, Ye W, Wolfe M, Selkoe D . Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc Natl Acad Sci U S A. 2003; 100(11):6382-7. PMC: 164455. DOI: 10.1073/pnas.1037392100. View

Flood D, Reaume A, Dorfman K, Lin Y, Lang D, Trusko S . FAD mutant PS-1 gene-targeted mice: increased A beta 42 and A beta deposition without APP overproduction. Neurobiol Aging. 2002; 23(3):335-48. DOI: 10.1016/s0197-4580(01)00330-x. View

Hook V, Kindy M, Hook G . Inhibitors of cathepsin B improve memory and reduce beta-amyloid in transgenic Alzheimer disease mice expressing the wild-type, but not the Swedish mutant, beta-secretase site of the amyloid precursor protein. J Biol Chem. 2008; 283(12):7745-53. DOI: 10.1074/jbc.M708362200. View

Cummings B, Satou T, Head E, Milgram N, Cole G, Savage M . Diffuse plaques contain C-terminal A beta 42 and not A beta 40: evidence from cats and dogs. Neurobiol Aging. 1996; 17(4):653-9. DOI: 10.1016/0197-4580(96)00062-0. View

Lambert M, Velasco P, Chang L, Viola K, Fernandez S, Lacor P . Monoclonal antibodies that target pathological assemblies of Abeta. J Neurochem. 2006; 100(1):23-35. DOI: 10.1111/j.1471-4159.2006.04157.x. View

Hussain I, Powell D, Howlett D, Chapman G, Gilmour L, Murdock P . ASP1 (BACE2) cleaves the amyloid precursor protein at the beta-secretase site. Mol Cell Neurosci. 2000; 16(5):609-19. DOI: 10.1006/mcne.2000.0884. View

Nilsson K, Aslund A, Berg I, Nystrom S, Konradsson P, Herland A . Imaging distinct conformational states of amyloid-beta fibrils in Alzheimer's disease using novel luminescent probes. ACS Chem Biol. 2007; 2(8):553-60. DOI: 10.1021/cb700116u. View

Bitan G, Kirkitadze M, Lomakin A, Vollers S, Benedek G, Teplow D . Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci U S A. 2002; 100(1):330-5. PMC: 140968. DOI: 10.1073/pnas.222681699. View

Steinerman J, Irizarry M, Scarmeas N, Raju S, Brandt J, Albert M . Distinct pools of beta-amyloid in Alzheimer disease-affected brain: a clinicopathologic study. Arch Neurol. 2008; 65(7):906-12. PMC: 2586606. DOI: 10.1001/archneur.65.7.906. View

10.

Selkoe D, Wolfe M . Presenilin: running with scissors in the membrane. Cell. 2007; 131(2):215-21. DOI: 10.1016/j.cell.2007.10.012. View

11.

Aguzzi A, Sigurdson C, Heikenwaelder M . Molecular mechanisms of prion pathogenesis. Annu Rev Pathol. 2008; 3:11-40. DOI: 10.1146/annurev.pathmechdis.3.121806.154326. View

12.

Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K . Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med. 2007; 13(11):1359-62. DOI: 10.1038/nm1653. View

13.

McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C . Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron. 2005; 47(2):191-199. PMC: 1373682. DOI: 10.1016/j.neuron.2005.06.030. View

14.

Sinha S, Anderson J, Barbour R, Basi G, Caccavello R, Davis D . Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature. 1999; 402(6761):537-40. DOI: 10.1038/990114. View

15.

Rosen R, Walker L, LeVine 3rd H . PIB binding in aged primate brain: enrichment of high-affinity sites in humans with Alzheimer's disease. Neurobiol Aging. 2009; 32(2):223-34. PMC: 2891164. DOI: 10.1016/j.neurobiolaging.2009.02.011. View

16.

Hasegawa M . Biochemistry and molecular biology of tauopathies. Neuropathology. 2006; 26(5):484-90. DOI: 10.1111/j.1440-1789.2006.00666.x. View

17.

Sun B, Zhou Y, Halabisky B, Lo I, Cho S, Mueller-Steiner S . Cystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer's disease. Neuron. 2008; 60(2):247-57. PMC: 2755563. DOI: 10.1016/j.neuron.2008.10.001. View

18.

Marr R, Rockenstein E, Mukherjee A, Kindy M, Hersh L, Gage F . Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci. 2003; 23(6):1992-6. PMC: 6742010. View

19.

Maruyama M, Higuchi M, Takaki Y, Matsuba Y, Tanji H, Nemoto M . Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease. Ann Neurol. 2005; 57(6):832-42. DOI: 10.1002/ana.20494. View

20.

Koffie R, Meyer-Luehmann M, Hashimoto T, Adams K, Mielke M, Garcia-Alloza M . Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A. 2009; 106(10):4012-7. PMC: 2656196. DOI: 10.1073/pnas.0811698106. View